 WEST CONSHOHOCKEN, Pa., June 08, 2021 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc NASDAQ: MDGL, a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis NASH, announced today its management team will participate in two upcoming virtual investor conferences: 